News
IVIXF
0.0018
NaN%
--
Invion Secures Up to A$2m Non-Dilutive Funding for Esophageal Cancer Program
TipRanks · 12/22/2025 23:57
Invion Secures Global Licensing for Photosoft™ Technology
TipRanks · 12/02/2025 22:58
Invion Limited Passes Key Resolutions at 2025 AGM
TipRanks · 11/26/2025 05:27
Invion Advances Photodynamic Therapy for Cancer and Infectious Diseases
TipRanks · 11/26/2025 03:38
Invion Limited to Hold Virtual AGM in November 2025
TipRanks · 10/23/2025 23:37
Invion Partners with Protect Animal Health to Explore Pet Cancer Treatment
TipRanks · 10/21/2025 01:17
Invion Strengthens Capital Structure with Successful Convertible Notes Issuance
Barchart · 10/10/2025 20:00
Invion Limited Announces Convertible Notes Issue
Barchart · 10/10/2025 20:00
Invion Limited Announces Proposed Securities Issue to Strengthen Market Position
Barchart · 10/10/2025 20:00
Invion Limited Initiates Trading Halt for Capital Raising Announcement
Barchart · 10/08/2025 19:28
Invion Director’s Securities Update Reflects Strategic Adjustment
TipRanks · 09/24/2025 05:22
Invion Limited Announces Cessation of Securities
TipRanks · 09/24/2025 05:22
Weekly Report: what happened at IVIXF last week (0908-0912)?
Weekly Report · 09/15/2025 11:53
Weekly Report: what happened at IVIXF last week (0901-0905)?
Weekly Report · 09/08/2025 11:55
Weekly Report: what happened at IVIXF last week (0825-0829)?
Weekly Report · 09/01/2025 11:49
Invion Secures FDA Orphan Drug Designation for Anal Cancer
TipRanks · 08/28/2025 02:57
More
Webull provides a variety of real-time IVIXF stock news. You can receive the latest news about Invion Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IVIXF
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.